Office of National Drug Control Policy (ONDCP) Funding and Resources
Open Funding Opportunities
Funding to address substance use disorders (SUDs) and related issues. List may include programs with a primary purpose other than addressing SUDs.
No funding programs from this federal agency are currently accepting applications.
Inactive Funding Opportunities
Many inactive programs are likely to be offered again. Grant deadlines are often short, and viewing inactive programs can give you a head start in applying next time.
Supports research projects that implement innovative strategies to reduce opioid, stimulant, and/or poly-drug overdose in high-risk communities. Promotes the use of evidence-based practices in new or existing programs and emphasizes the evaluation of new and promising approaches. Establishes partnerships between public safety and public health agencies to address harms related to opioid, stimulant, and poly-substance use and overdose.
Resources
Outlines federal drug policy priorities and promotes short and long-term solutions to reduce drug use, overdose, supply, and other related harms in the U.S. Covers information and strategies to prevent youth substance use, expand access to medications for opioid use disorder and other evidence-based treatments, building recovery communities, and strengthening efforts to disrupt drug trafficking. Includes strategies to address substance use issues in rural, tribal, and other underserved communities.
Identifies and describes the following 7 drug policy priorities for the first year of the Biden-Harris Administration: expanding access to evidence-based treatment; advancing racial equity issues in drug policy; enhancing evidenced-based harm reduction efforts; supporting evidence-based prevention efforts to reduce youth substance use; reducing the supply of illicit substances; advancing recovery-ready workplaces and increasing the addiction workforce; and expanding access to recovery support services. Outlines next steps for the Office of National Drug Control Policy (ONDCP) to coordinate with other federal agencies to address drug policy priorities.
Provides a brief outline of the Drug-Free Communities (DFC) Support Program and summarizes national DFC program implementation evaluation data from February to August 2022. Describes the reach of the DFC program, substances addressed, community protective and risk factors, and the types of communities served, including rural and frontier areas.
Interactive map providing data on suspected nonfatal drug overdoses in pre-hospital care settings in the U.S. at the national, state, and county level. Offers data on nonfatal drug overdose incidence and trends, including overdose rates, number/rate of naloxone administration, and average emergency medical services (EMS) response time. Allows users to explore disparities according to demographic characteristics, such as age, race, gender, and frontier, rural, and urban geographies, as well as by the suspected drug involved.
Consists of a public health and public safety collaboration between the High Intensity Drug Trafficking Areas (HIDTA) program and the Centers for Disease Control and Prevention (CDC) across the U.S. Seeks to help communities reduce fatal and non-fatal drug overdose rates by improving information sharing across agencies and supporting evidence-based interventions. Equips states with a Drug Intelligence Officer (DIO) and a Public Health Analyst (PHA) who are responsible for helping to increase communication, data flow, and intelligence sharing between public safety and public health sectors within and across states.
Video recording of a workshop discussion intended to help rural faith leaders understand substance use prevention and identify and implement evidence-based prevention strategies in rural communities. Provides information on substance use prevention, treatment, and recovery in a rural context. Highlights ways that faith communities can partner with other stakeholders to develop prevention programs and activities and offers several faith-based prevention program models.